Sintilimab plus platinum-based chemotherapy for non-squamous NSCLC

被引：0
|
作者：
Venkatesan, Priya
机构：
来源：
LANCET RESPIRATORY MEDICINE | 2020年 / 8卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：E76 / E76
页数：1
相关论文
共 50 条
  • [1] A Randomized Phase II Study of Platinum-Based Chemotherapy plus /-Metformin in Chemotherapy-Naive Advanced Non-Squamous NSCLC
    Marrone, Kristen
    Forde, Patrick
    Brahmer, Julie
    Rosner, Gary
    Zhou, Xian
    Coleman, Barbara
    Ettinger, David
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S893 - S893
  • [2] Pemetrexed plus Platinum Chemotherapy with or Without Immunotherapy in Non-Squamous NSCLC: Descriptive Safety Analysis
    Govindan, R.
    Borghaei, H.
    He, S.
    Kim, J. S.
    Papadimitrakopoulou, V.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2083 - S2084
  • [3] ORIENT-11: Sintilimab plus Pemetrexed plus Platinum as First-Line Therapy for Locally Advanced or Metastatic Non-Squamous NSCLC
    Zhang, L.
    Yang, Y.
    Wang, Z.
    Fang, J.
    Yu, Q.
    Han, B.
    Cang, S.
    Chen, G.
    Mei, X.
    Yang, Z.
    Ma, R.
    Bi, M.
    Ren, X.
    Zhou, J.
    Li, B.
    Xu, W.
    Ji, Y.
    Peng, B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (10) : E41 - E41
  • [4] BR-34-Randomized Trial of Durvalumab and Tremelimumab plus /- Platinum Chemotherapy in Patients with Metastatic Squamous or Non-Squamous NSCLC
    Kulkarni, S.
    Laurie, S.
    Goss, G.
    Perrone, F.
    Hughes, B.
    Pavlakis, N.
    Stockler, M.
    Blais, A.
    Zibdawi, L.
    Vera-Badillo, F.
    Leighl, N.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S480 - S481
  • [5] First Line Sintilimab plus Anlotinib vs Platinum-based Chemotherapy in Metastatic NSCLC (SUNRISE): Updated Efficacy and Safety Analysis
    Chu, T.
    Han, B.
    Yu, Z.
    Wang, J.
    Zhao, Y.
    Mu, X.
    Yu, X.
    Shi, X.
    Shi, Q.
    Guan, M.
    Ding, C.
    Geng, N.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S616 - S616
  • [6] Pharmacogenomics of platinum-based chemotherapy in NSCLC
    Hildebrandt, Michelle A. T.
    Gu, Jian
    Wu, Xifeng
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (07) : 745 - 755
  • [7] The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy
    Kastritis, E
    Bamias, A
    Efstathiou, E
    Gika, D
    Bozas, G
    Zorzou, P
    Sarris, K
    Papadimitriou, C
    Dimopoulos, MA
    [J]. GYNECOLOGIC ONCOLOGY, 2005, 99 (02) : 376 - 382
  • [8] COMPARISON OF EFFICACY OF PEMETREXED PLUS PLATINUM AND NON-PEMETREXED PLUS PLATINUM AS 1ST LINE CHEMOTHERAPY IN EGFR WILD TYPE NON-SQUAMOUS NSCLC
    Kang, E. J.
    Lee, S. Y.
    Kim, J. S.
    [J]. ANNALS OF ONCOLOGY, 2015, 26
  • [9] Sintilimab ± IBI305 Plus Chemotherapy for Patients With EGFR-Mutant Non-Squamous NSCLC Failed to EGFR-TKI Treatment
    Lu, S.
    Cheng, Y.
    Wu, L.
    Fang, J.
    Li, B.
    Han, L.
    Zhang, Y.
    Pan, H.
    Wang, Z.
    Sun, Y.
    Ye, F.
    Hu, Y.
    Yu, W.
    Zhou, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S649 - S649
  • [10] IMpower132: A phase III clinical program-1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC.
    West, Howard Jack
    Nishio, Makoto
    Dols, Manuel Cobo
    Saito, Haruhiro
    Howland, Michael
    Hoang, Tien
    Asakawa, Takashi
    Sandler, Alan
    Socinski, Mark A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345